Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use REBIF safely and effectively. See full prescribing information for REBIF. REBIF (interferon beta-1a), for subcutaneous injection Initial U.S. Approval: 1996
Medication labelWhy this: Advisory · dailymed-prescription
REBIF is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
- generic_name
- interferon beta-1a
- product_names
- interferon beta-1a, INTERFERON BETA-1A
- ndc
- 44087-8822, 44087-8822-1, 44087-0188, 44087-0188-1, 44087-0022, 44087-0022-9, 44087-0022-3, 44087-0044, 44087-0044-9, 44087-0044-3, 44087-3322, 44087-3322-9, 44087-3322-1, 44087-3344, 44087-3344-9, 44087-3344-1
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en